JP4106263B2 - 炎症性の状態の治療のためのｐｐａｒデルタ活性化因子の使用 - Google Patents

炎症性の状態の治療のためのｐｐａｒデルタ活性化因子の使用 Download PDF

Info

Publication number
JP4106263B2
JP4106263B2 JP2002532258A JP2002532258A JP4106263B2 JP 4106263 B2 JP4106263 B2 JP 4106263B2 JP 2002532258 A JP2002532258 A JP 2002532258A JP 2002532258 A JP2002532258 A JP 2002532258A JP 4106263 B2 JP4106263 B2 JP 4106263B2
Authority
JP
Japan
Prior art keywords
methyl
acid
activator
compound
inos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002532258A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004510750A (ja
JP2004510750A5 (enExample
Inventor
バカン，ケヴィン，ウィリアム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2004510750A publication Critical patent/JP2004510750A/ja
Publication of JP2004510750A5 publication Critical patent/JP2004510750A5/ja
Application granted granted Critical
Publication of JP4106263B2 publication Critical patent/JP4106263B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
JP2002532258A 2000-10-05 2001-10-01 炎症性の状態の治療のためのｐｐａｒデルタ活性化因子の使用 Expired - Fee Related JP4106263B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0024361.8A GB0024361D0 (en) 2000-10-05 2000-10-05 Medicaments
PCT/GB2001/004373 WO2002028434A2 (en) 2000-10-05 2001-10-01 Use of a ppar delta activator for treating inflammatory conditions

Publications (3)

Publication Number Publication Date
JP2004510750A JP2004510750A (ja) 2004-04-08
JP2004510750A5 JP2004510750A5 (enExample) 2005-12-22
JP4106263B2 true JP4106263B2 (ja) 2008-06-25

Family

ID=9900709

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002532258A Expired - Fee Related JP4106263B2 (ja) 2000-10-05 2001-10-01 炎症性の状態の治療のためのｐｐａｒデルタ活性化因子の使用

Country Status (9)

Country Link
US (1) US7084161B2 (enExample)
EP (1) EP1324774B1 (enExample)
JP (1) JP4106263B2 (enExample)
AT (1) ATE318615T1 (enExample)
AU (1) AU2001292046A1 (enExample)
DE (1) DE60117584T2 (enExample)
ES (1) ES2259675T3 (enExample)
GB (1) GB0024361D0 (enExample)
WO (1) WO2002028434A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002243778A1 (en) * 2001-02-02 2002-09-19 Smithkline Beecham Corporation Treatment of ppar mediated diseases
CA2449247A1 (en) * 2001-06-11 2002-12-19 Merck & Co., Inc. A method for treating inflammatory diseases by administering a ppar-delta agonist
IL160845A0 (en) 2001-09-14 2004-08-31 Tularik Inc Linked biaryl compounds
FR2836829B1 (fr) * 2002-03-11 2005-11-25 Bio Merieux Utilisation de l-alpha-lysophosphatidylcholine pour obtenir la differenciation de monocytes en cellules dendritiques matures in vitro
JP2007530703A (ja) * 2004-04-01 2007-11-01 アベンティス・ファーマスーティカルズ・インコーポレイテツド Ｍｓおよびその他の脱髄疾患を治療するためのペルオキシソーム増殖因子活性化受容体デルタアゴニストの使用
WO2005105726A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
EP1745014B1 (en) 2004-05-05 2011-07-06 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
DE602005020313D1 (de) 2004-08-12 2010-05-12 Amgen Inc Bisaryl-sulfonamide
EP2298742B1 (en) 2005-06-30 2014-01-08 High Point Pharmaceuticals, LLC phenoxy acetic acids as PPAR delta activators
EP2386540A1 (en) 2005-12-22 2011-11-16 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
CA2645719A1 (en) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Compounds that modulate ppar activity, their preparation and use
US20080004281A1 (en) * 2006-06-28 2008-01-03 Kalypsys, Inc. Methods for the modulation of crp by the selective modulation of ppar delta
BRPI0811612A2 (pt) * 2007-05-21 2014-11-11 Senju Pharma Co Composições farmacêuticas que contêm agonista ppardelta
EP2464349A2 (en) * 2009-08-14 2012-06-20 Cerenis Therapeutics S.A. Use of ppar delta ligands for the treatment or prevention of inflammation or energy metabolism/production related diseases
KR102038866B1 (ko) * 2012-12-24 2019-10-31 서울대학교산학협력단 ＰＰＡＲδ 활성물질의 항생제, 화상 및 창상 치료제, 당뇨성 족부궤양 치료제로서의 용도
WO2015035171A1 (en) 2013-09-09 2015-03-12 High Point Pharmaceuticals, Llc Use of a ppar-delta agonist for treating muscle atrophy
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease
KR102750722B1 (ko) * 2022-03-16 2025-01-09 재단법인 대구경북첨단의료산업진흥재단 싸이아다이아졸 화합물 및 이를 포함하는 염증성 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028149A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
US6300364B1 (en) 1997-07-24 2001-10-09 Yamanouchi Pharmaceutical Co., Ltd. Medicinal compositions with cholesterol-lowering effect
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
ATE318615T1 (de) 2006-03-15
DE60117584T2 (de) 2006-12-21
US7084161B2 (en) 2006-08-01
JP2004510750A (ja) 2004-04-08
ES2259675T3 (es) 2006-10-16
DE60117584D1 (de) 2006-04-27
EP1324774B1 (en) 2006-03-01
EP1324774A2 (en) 2003-07-09
WO2002028434A2 (en) 2002-04-11
GB0024361D0 (en) 2000-11-22
US20050131035A1 (en) 2005-06-16
AU2001292046A1 (en) 2002-04-15
WO2002028434A3 (en) 2002-08-15

Similar Documents

Publication Publication Date Title
JP4106263B2 (ja) 炎症性の状態の治療のためのｐｐａｒデルタ活性化因子の使用
EP2776425B1 (en) New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
US8975235B2 (en) Lysophosphatidic acid receptor antagonists
JP2022521824A (ja) アンドロゲン受容体の阻害剤を含む薬学的組成物及びその組み合わせならびにその使用
TWI401082B (zh) 作為溶血磷脂酸受體拮抗劑之化合物
AU2012333988A1 (en) New cyclohexylamine derivatives having beta 2 adrenergic agonist and M3 muscarinic antagonist activities
US20140200215A1 (en) Lysophosphatidic acid receptor antagonists
JP2011513242A (ja) プロスタグランジンｄ２受容体アンタゴニスト
JP2003525217A (ja) 肥満治療用薬剤
JP2003507327A (ja) 化学化合物
WO2009102893A2 (en) CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors
JP2006517564A (ja) Ｎｕｒｒ−１アクチベーターとして有用な複素環化合物
US8030324B2 (en) Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia
WO2010006496A1 (zh) 用作雌激素相关受体调节剂的化合物及其应用
JP2004510749A (ja) Ｎｏ阻害またはｔｎｆ阻害に関連した疾病の治療におけるｐｐａｒデルタ活性化因子の使用
JP2019147807A (ja) 肝臓ｘ受容体（ｌｘｒ）のモジュレーター
JP2002529458A (ja) ＰＰＡＲ−γリガンド
JP7107963B2 (ja) 置換されたｎ－アリールエチル－２－アリールキノリン－４－カルボキサミド類及びそれの使用
AU2006263884A1 (en) Quinoline derivatives as antibacterial agents
NZ624784B2 (en) New cyclohexylamine derivatives having ?2 adrenergic agonist and m3 muscarinic antagonist activities
HK1223015B (zh) 使用甲基巴多索隆或其类似物治疗和预防内皮功能障碍的方法
JPWO1999021844A1 (ja) 抗リウマチ剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080311

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080331

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110404

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees